Cervarix
| Vaccine description | |
|---|---|
| Target | human papillomavirus (Types 16 and 18) |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Cervarix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610014 |
| Routes of administration | Intramuscular injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (what is this?) (verify) | |
Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).
Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases. These types also cause most HPV-induced genital and head and neck cancers. Additionally, some cross-reactive protection against virus strains 45 and 31 were shown in clinical trials. Cervarix also contains AS04, a proprietary adjuvant that has been found to boost the immune system response for a longer period of time.
Cervarix is manufactured by GlaxoSmithKline. An alternative product, from Merck & Co., is known as Gardasil. Cervarix was voluntarily taken off of the market in the US in 2016 due to low demand.